









Markets
/
Stocks
/
nasdaq-alzn
/

Alzamend Neuro Inc

ALZN

2.390USD

+0.040+1.70%

Market hours （ET）Quotes delayed by 15 min

7.50MMarket Cap

LossP/E TTM



Alzamend Neuro Inc

2.390

+0.040+1.70%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Alzamend Neuro Inc

Currency: USD Updated: 2025-10-20

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very low. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Alzamend Neuro Inc's Score

Industry at a Glance

Industry Ranking

305 / 501

Overall Ranking

544 / 4689

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

42.000

Target Price

+1791.89%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Alzamend Neuro Inc Highlights

StrengthsRisks

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.

Overvalued

The company’s latest PE is -0.03, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.79K shares, decreasing 83.48% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 600.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-20

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Alzamend Neuro Inc's Company Valuation

Currency: USD Updated: 2025-10-20

The company’s current valuation score is 8.55, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -0.03, which is -16.41% below the recent high of -0.02 and -54777325.00% above the recent low of -14023.02.

Score

Industry at a Glance

Previous score

8.55

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 305/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-20

The company’s current earnings forecast score is 7.00, which is lower than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Alzamend Neuro Inc is 42.00, with a high of 42.00 and a low of 42.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

42.000

Target Price

+1687.23%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Alzamend Neuro Inc

ALZN

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-20

The company’s current price momentum score is 1.21, which is lower than the Biotechnology & Medical Research industry's average of 6.96. Sideways: Currently, the stock price is trading between the resistance level at 2.60 and the support level at 2.11, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.18

Change

0.03

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.017

Sell

RSI(14)

48.656

Neutral

STOCH(KDJ)(9,3,3)

36.600

Neutral

ATR(14)

0.166

Low Volatility

CCI(14)

-46.053

Neutral

Williams %R

55.102

Sell

TRIX(12,20)

-0.203

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

2.298

Buy

MA10

2.322

Buy

MA20

2.373

Buy

MA50

2.391

Sell

MA100

2.735

Sell

MA200

5.281

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-20

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 0.08%, representing a quarter-over-quarter decrease of 97.57%. The largest institutional shareholder is The Vanguard, holding a total of 600.00 shares, representing 0.02% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Ault (Milton C III)

44.61K

+110.10%

Horne (William B)

3.33K

UBS Financial Services, Inc.

902.00

Tower Research Capital LLC

797.00

Katzoff (David J)

615.00

The Vanguard Group, Inc.

Star Investors

600.00

BlackRock Institutional Trust Company, N.A.

441.00

Woo (Andrew H)

74.00

Oram (Jeffrey)

74.00

McGrath (Lynne Fahey)

55.00

-1.79%

Risk Assessment

Currency: USD Updated: 2025-10-20

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is -0.28. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.